Drug Trial Radar · NCT03374475
A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Jan 5, 2018
Primary completion
Apr 29, 2019
Study completion Apr 29, 2019
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to explore if the magnitude of treatment effect (JNJ-42847922; placebo) on symptoms of depression (as measured by Hamilton rating scale for depression-17 \[HDRS17\], Sleep item-adjusted HDRS17, Anxiety/somatization factor score and the 6-item subscale from HDRS17 \[HAM-D6\]) differs across different levels of hyper-arousal status (characterized by Sleep parameters, ruminative response scale \[RRS\], Sleep and Worry visual analogue scale \[VAS\], quantitative electro-encephalography \[qEEG\], heart rate variability \[HRV\] and others).
Conditions
- Depressive Disorder, Major
Interventions
JNJ-42847922 20mgDrug
Participants will swallow 20 mg (2\*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
JNJ-42847922 40mgDrug
Participants will swallow 40 mg (2\*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
PlaceboDrug
All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Total ScoreTime frame: Baseline up to Day 57
- Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Sleep Item-Adjusted Total ScoreTime frame: Baseline up to Day 57
- Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Anxiety/Somatization Factor ScoreTime frame: Baseline up to Day 57
- Change From Baseline in 6 Item Subscale From HDRS17 (HAM-D6) ScoreTime frame: Baseline up to Day 57
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Artemis Institute for Clinical Research
San Diego, California
Artemis Institute for Clinical Research
San Marcos, California
Qps-Mra, Llc
Miami, Florida
SGS Phase 1 Unit AZ St-Maarten
Mechelen, Belgium
Clinical Pharmacology Unit
Merksem, Belgium
Charite Research Organisation GmbH
Berlin, Germany
Emovis GmbH
Berlin, Germany
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin
Hanover, Germany
Somni Bene GmbH
Schwerin, Germany
Centre for Human Drug Research
Leiden, Netherlands
MAC Clinical Research
Blackpool, United Kingdom
MAC Clinical Research
Liverpool, United Kingdom
Hammersmith Medicines Research
London, United Kingdom
MAC Clinical Research
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.